Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 797

1.

CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.

Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, Manjili MH.

Hum Pathol. 2012 Mar;43(3):364-73. doi: 10.1016/j.humpath.2011.05.005. Epub 2011 Aug 10.

PMID:
21835433
2.

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.

Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.

Breast Cancer Res Treat. 2010 Jul;122(2):315-24. doi: 10.1007/s10549-009-0568-x. Epub 2009 Oct 1.

PMID:
19795205
3.

Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.

Hashimoto K, Shimizu C, Tsuda H, Saji S, Osaki A, Shigekawa T, Aogi K.

Oncology. 2012;82(3):168-74. doi: 10.1159/000336078. Epub 2012 Mar 15.

PMID:
22433454
4.

Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.

Currie MJ, Beardsley BE, Harris GC, Gunningham SP, Dachs GU, Dijkstra B, Morrin HR, Wells JE, Robinson BA.

Hum Pathol. 2013 Mar;44(3):402-11. doi: 10.1016/j.humpath.2012.06.004. Epub 2012 Oct 1.

PMID:
23036368
5.

The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.

Breast Cancer Res. 2008;10(3):R53. doi: 10.1186/bcr2108. Epub 2008 Jun 17.

6.

Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer.

Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares FA, Brentani MM.

Oncol Rep. 2012 Jan;27(1):28-38. doi: 10.3892/or.2011.1477. Epub 2011 Sep 28.

PMID:
21956537
7.

ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.

Zhong Y, Shen S, Zhou Y, Mao F, Guan J, Lin Y, Xu Y, Sun Q.

Med Oncol. 2014 Mar;31(3):864. doi: 10.1007/s12032-014-0864-0. Epub 2014 Feb 12.

PMID:
24519209
8.

Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.

Kagara N, Huynh KT, Kuo C, Okano H, Sim MS, Elashoff D, Chong K, Giuliano AE, Hoon DS.

Am J Pathol. 2012 Jul;181(1):257-67. doi: 10.1016/j.ajpath.2012.03.019. Epub 2012 May 21.

PMID:
22626806
9.

Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Wang Z, Shi Q, Wang Z, Gu Y, Shen Y, Sun M, Deng M, Zhang H, Fang J, Zhang S, Xie F.

Pathol Res Pract. 2011 Aug 15;207(8):505-13. doi: 10.1016/j.prp.2011.06.009. Epub 2011 Jul 28.

PMID:
21802218
10.

The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.

Li W, Liu F, Lei T, Xu X, Liu B, Cui L, Wei J, Guo X, Lang R, Fan Y, Gu F, Tang P, Zhang X, Fu L.

Pathol Res Pract. 2010 Dec 15;206(12):828-34. doi: 10.1016/j.prp.2010.09.008. Epub 2010 Oct 24.

PMID:
20977976
11.

Characteristic genes in luminal subtype breast tumors with CD44+CD24-/low gene expression signature.

Tsunoda Y, Sakamoto M, Sawada T, Sasaki A, Yamamoto G, Tachikawa T.

Oncology. 2011;81(5-6):336-44. doi: 10.1159/000334690. Epub 2012 Jan 11.

PMID:
22237177
12.

CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.

Lü X, Xu K, Lü H, Yin Y, Ma C, Liu Y, Li H, Suo Z.

Ultrastruct Pathol. 2011 Apr;35(2):72-8. doi: 10.3109/01913123.2010.544843.

PMID:
21299347
13.

Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer.

Nogi H, Suzuki M, Kamio M, Kato K, Kawase K, Toriumi Y, Takeyama H, Fukushima H, Morikawa T, Uchida K.

Oncol Rep. 2011 Apr;25(4):1109-15. doi: 10.3892/or.2011.1177. Epub 2011 Feb 9.

PMID:
21308353
14.

Functional heterogeneity within the CD44 high human breast cancer stem cell-like compartment reveals a gene signature predictive of distant metastasis.

Leth-Larsen R, Terp MG, Christensen AG, Elias D, Kühlwein T, Jensen ON, Petersen OW, Ditzel HJ.

Mol Med. 2012 Sep 25;18:1109-21. doi: 10.2119/molmed.2012.00091.

15.

The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.

Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI.

Med Oncol. 2011 Sep;28(3):745-52. doi: 10.1007/s12032-010-9530-3. Epub 2010 Apr 20.

PMID:
20405247
16.

Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.

Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J.

J Clin Pathol. 2011 Nov;64(11):937-46. doi: 10.1136/jcp.2011.090456. Epub 2011 Jun 16.

PMID:
21680574
17.
18.

Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.

Vesuna F, Lisok A, Kimble B, Raman V.

Neoplasia. 2009 Dec;11(12):1318-28.

19.

A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.

Ahmed MA, Aleskandarany MA, Rakha EA, Moustafa RZ, Benhasouna A, Nolan C, Green AR, Ilyas M, Ellis IO.

Breast Cancer Res Treat. 2012 Jun;133(3):979-95. doi: 10.1007/s10549-011-1865-8. Epub 2011 Nov 27.

PMID:
22119938
20.

Distribution of CD44/CD24 positive cells in ductal invasive carcinoma of breast of different grade and molecular subtype.

Gudadze M, Kankava K, Mariamidze A, Mosidze T, Burkadze G.

Georgian Med News. 2013 Sep;(222):50-7.

PMID:
24099815
Items per page

Supplemental Content

Write to the Help Desk